Anidulafungin

Anidulafungin
Product Description

Status:
DMF No.: 032010                                              
ASMF Approved
Patent Expiration: Off-patentUsage: Antifungal

BrightGene Bio-Medical Technology Co.,Ltd.

  • CN
  • 2015
    On CPHI since
Specifications
  • CAS Registry Number
    166663-25-8
  • Selling Points
    Quality Service
  • Supplied from
    China

BrightGene Bio-Medical Technology Co.,Ltd.

  • CN
  • 2015
    On CPHI since

More Products from BrightGene Bio-Medical Technology Co.,Ltd. (49)

  • Dydrogesterone

    Product Dydrogesterone

    • Status: Pilot • Patent Expiration: Off-patent • Usage: Progestogens
  • Oritavancin

    Product Oritavancin

    • Status: Pre-validation • Patent Expiration: Off-patent • Usage: Anti-infection
  • Pimecrolimus

    Product Pimecrolimus

    • Status: DMF No.: 030090 • Patent Expiration: Off-patent • Usage: Immunosuppressant
  • Everolimus(without BHT)

    Product Everolimus(without BHT)

    • Status: MF No.: 230MF10023 • Patent Expiration: Off-patent • Usage: Oncology
  • Midostaurin

    Product Midostaurin

    • Status: Validated • Patent Expiration: Off-patent • Usage: Oncology
  • Fondaparinux Sodium

    Product Fondaparinux Sodium

    • Status: DMF No. :030767 • Patent Expiration: Off-patent • Usage:Anticoagulant
  • Argatroban Monohydrate

    Product Argatroban Monohydrate

    • Status: MF No.: 230MF10028; USDMF to be filed in Q4,2020 • Patent Expiration: Off-patent • Usage:Anticoagulant
  • Caspofungin Acetate

    Product Caspofungin Acetate

    • Status: ASMF Approved & DMF No.:034091 • Patent Expiration:Off-patent • Usage:Antifungal
  • Entecavir monohydrate

    Product Entecavir monohydrate

    Brightgene Bio-Medical Technology Co.Ltd. Offers a wide range of anti-infective products which includes entecavir monohydrate. It belongs to anti-viral category. Contact us for more information. • Status: DMF No.:031949 • Patent Expiration: Off-patent • Usage:AntiHBV
  • Eribulin Mesilate

    Product Eribulin Mesilate

    • Status: Validated • Patent Expiration: US:2023.07.20 ;CN:off-patent • Usage: Oncology
  • Everolimus(2.0% BHT)

    Product Everolimus(2.0% BHT)

    • Status: DMF No.:032020 • Patent Expiration: Off-patent • Usage: Oncology
  • Fidaxomicin

    Product Fidaxomicin

    • Status: DMF No.: 028803 • Patent Expiration: US:2027.03.04; • Usage: Anti-infection